Geographical Location stringclasses 54
values | Report Date stringclasses 1
value | MDS Item Question/Description stringclasses 828
values | MDS Item Response stringclasses 303
values | Percent stringlengths 1 5 | Total Residents stringlengths 1 7 |
|---|---|---|---|---|---|
District of Columbia | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
District of Columbia | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Florida | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 38.01 | 149 |
Florida | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 61.99 | 243 |
Georgia | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 50.98 | 52 |
Georgia | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 49.02 | 50 |
Hawaii | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Hawaii | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Idaho | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Idaho | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Illinois | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 56.13 | 151 |
Illinois | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 43.87 | 118 |
Indiana | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 47.62 | 50 |
Indiana | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 52.38 | 55 |
Iowa | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 48.84 | 21 |
Iowa | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 51.16 | 22 |
Kansas | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 46.51 | 20 |
Kansas | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 53.49 | 23 |
Kentucky | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 43.66 | 31 |
Kentucky | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 56.34 | 40 |
Louisiana | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 57.47 | 50 |
Louisiana | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 42.53 | 37 |
Maine | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Maine | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Maryland | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 38.14 | 45 |
Maryland | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 61.86 | 73 |
Massachusetts | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 56.25 | 81 |
Massachusetts | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 43.75 | 63 |
Michigan | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 34.65 | 44 |
Michigan | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 65.35 | 83 |
Minnesota | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 28.57 | 12 |
Minnesota | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 71.43 | 30 |
Mississippi | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 48.48 | 32 |
Mississippi | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 51.52 | 34 |
Missouri | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 47.19 | 42 |
Missouri | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 52.81 | 47 |
Montana | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Montana | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Nebraska | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 48 | 12 |
Nebraska | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 52 | 13 |
Nevada | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Nevada | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 65 | 13 |
New Hampshire | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
New Hampshire | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
New Jersey | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 45.55 | 133 |
New Jersey | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 54.45 | 159 |
New Mexico | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
New Mexico | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
New York | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 33.02 | 173 |
New York | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 66.98 | 351 |
North Carolina | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 43.64 | 48 |
North Carolina | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 56.36 | 62 |
North Dakota | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
North Dakota | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Ohio | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 56.04 | 116 |
Ohio | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 43.96 | 91 |
Oklahoma | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 29.63 | 16 |
Oklahoma | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 70.37 | 38 |
Oregon | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 64.71 | 11 |
Oregon | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Pennsylvania | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 44.56 | 86 |
Pennsylvania | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 55.44 | 107 |
Puerto Rico | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Puerto Rico | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Rhode Island | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Rhode Island | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
South Carolina | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 47.46 | 28 |
South Carolina | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 52.54 | 31 |
South Dakota | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
South Dakota | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Tennessee | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 56.67 | 51 |
Tennessee | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 43.33 | 39 |
Texas | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 49.78 | 115 |
Texas | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 50.22 | 116 |
Utah | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Utah | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Vermont | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Vermont | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Virgin Islands | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Virgin Islands | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
Virginia | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 51.02 | 50 |
Virginia | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 48.98 | 48 |
Washington | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 53.06 | 26 |
Washington | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 46.94 | 23 |
West Virginia | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 50 | 11 |
West Virginia | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 50 | 11 |
Wisconsin | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 53.57 | 30 |
Wisconsin | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 46.43 | 26 |
Wyoming | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | * | * |
Wyoming | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | * | * |
National Total | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | Yes | 46.37 | 2162 |
National Total | Q1, 2025 | A2122C: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Verbal (e.g., in-person, telephone, video conferencing) | No | 53.63 | 2500 |
Alabama | Q1, 2025 | A2122D: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Paper-based (e.g., fax, copies, printouts) | Yes | 94.92 | 56 |
Alabama | Q1, 2025 | A2122D: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Paper-based (e.g., fax, copies, printouts) | No | * | * |
Alaska | Q1, 2025 | A2122D: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Paper-based (e.g., fax, copies, printouts) | Yes | * | * |
Alaska | Q1, 2025 | A2122D: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Paper-based (e.g., fax, copies, printouts) | No | * | * |
Arizona | Q1, 2025 | A2122D: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Paper-based (e.g., fax, copies, printouts) | Yes | 94.74 | 36 |
Arizona | Q1, 2025 | A2122D: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Paper-based (e.g., fax, copies, printouts) | No | * | * |
Arkansas | Q1, 2025 | A2122D: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Paper-based (e.g., fax, copies, printouts) | No | * | * |
Arkansas | Q1, 2025 | A2122D: Identification Information - Route of Current Reconciled Medication List Transmission to Subsequent Provider: Paper-based (e.g., fax, copies, printouts) | Yes | 97.14 | 34 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.